Loading cancer entity…
Loading cancer entity…
Clinical trials
6,745 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,044)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07833202 | A Phase 3 Study of Sosimerasib in Combination With IN10018 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation | not yet recruiting | Phase 3 | 416 | Shanghai Jeyou Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07838532 | Real-World Study of Aumolertinib in Patients With Advanced EGFR T790M-Positive NSCLC(AUMO-RWE) | completed | — | 637 | Xin LiOTHER | 1 | Sep 24, 2026 |
| clinicaltrials |
| NCT02194738 | Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) | active not recruiting | N/A | 7,458 | National Cancer Institute (NCI)NIH | 3 | Sep 23, 2026 | clinicaltrials |
| NCT03340506 | Dabrafenib and/or Trametinib Rollover Study | recruiting | Phase 4 | 100 | Novartis PharmaceuticalsINDUSTRY | 14 | Sep 23, 2026 | clinicaltrials |
| NCT03381274 | Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study | active not recruiting | Phase 1 / Phase 2 | 43 | MedImmune LLCINDUSTRY | 3 | Sep 23, 2026 | clinicaltrials |
| NCT04044859 | ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS) | active not recruiting | Phase 1 | 120 | USWM CT, LLCINDUSTRY | 3 | Sep 23, 2026 | clinicaltrials |
| NCT04062708 | CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer | active not recruiting | Phase 2 | 38 | Alliance Foundation Trials, LLC.OTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT05061550 | Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer(NeoCOAST-2) | recruiting | Phase 2 | 630 | AstraZenecaINDUSTRY | 12 | Sep 23, 2026 | clinicaltrials |
| NCT05144997 | Lorlatinib Continuation Study | active not recruiting | Phase 4 | 76 | PfizerINDUSTRY | 8 | Sep 23, 2026 | clinicaltrials |
| NCT05312840 | Efficacy and Safety of Conventional and Low-dose Platinum Gemcitabine Combined With Sintilimab With Delayed Administration in First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer | completed | Phase 2 | 20 | People's Hospital of QuzhouOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT05607108 | A Study of ZEN003694 in People With Squamous Cell Lung Cancer | recruiting | Phase 2 | 13 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT05715229 | Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy(G360-IIT) | terminated | Phase 2 | 5 | Hackensack Meridian HealthOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT06253520 | Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer | active not recruiting | Phase 1 | 210 | National Cancer Institute (NCI)NIH | 1 | Sep 23, 2026 | clinicaltrials |
| NCT06337552 | High-Fermented Food Intervention Among Locally Advanced Rectal Cancer Patients (The FEED Trial) | active not recruiting | N/A | 39 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT06357533 | Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations(TROPION-Lung10) | recruiting | Phase 3 | 675 | AstraZenecaINDUSTRY | 21 | Sep 23, 2026 | clinicaltrials |
| NCT06491862 | RACE-2L: Real-World Assessment of Clinical Practice and Outcomes in Non-squamous NSCLC After Failure of Platinum-based Chemotherapy in Brazil(RACE-2L) | recruiting | — | 250 | AstraZenecaINDUSTRY | 1 | Sep 23, 2026 | clinicaltrials |
| NCT06561386 | A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%(RELATIVITY1093) | recruiting | Phase 3 | 1,000 | Bristol-Myers SquibbINDUSTRY | 31 | Sep 23, 2026 | clinicaltrials |
| NCT06564844 | A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features(TROPION-Lung12) | active not recruiting | Phase 3 | 25 | AstraZenecaINDUSTRY | 10 | Sep 23, 2026 | clinicaltrials |
| NCT06627647 | A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC | recruiting | Phase 3 | 1,160 | AstraZenecaINDUSTRY | 25 | Sep 23, 2026 | clinicaltrials |
| NCT07140016 | A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC) | recruiting | Phase 1 | 40 | Astellas Pharma Global Development, Inc.INDUSTRY | 3 | Sep 23, 2026 | clinicaltrials |
| NCT07339176 | Intratumoral N17350 in Advanced Solid Tumors(OP-NEU-101) | recruiting | Phase 1 / Phase 2 | 275 | Onchilles Pharma IncINDUSTRY | 2 | Sep 23, 2026 | clinicaltrials |
| NCT07661966 | Bright Light Therapy in Patients With Melanoma or Non-small Cell Lung Cancer (NSCLC) Who Are Receiving First-Line Immune Checkpoint Blockade(IIT BLT) | recruiting | N/A | 12 | Weill Medical College of Cornell UniversityOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07822880 | A Study of Selpercatinib (LY3527723) in Participants With Rearranged During Transfection (RET)-Altered Cancers in India | not yet recruiting | Phase 4 | 30 | Eli Lilly and CompanyINDUSTRY | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07836543 | Trastuzumab Rezetecan and Adebrelimab, Alone or in Combination, After Chemoradiotherapy for HER2-Altered Unresectable Stage III Lung Cancer | not yet recruiting | Phase 2 | 105 | Ming ChenOTHER | 0 | Sep 23, 2026 | clinicaltrials |
| NCT07837739 | Adjuvant EGFR-TKI Therapy After Surgery for EGFR-Mutant High-Risk Stage IA2-IIB NSCLC | recruiting | — | 100 | Tongji HospitalOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT03965689 | Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy | active not recruiting | Phase 2 | 27 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT05009836 | Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC(SANOVO) | active not recruiting | Phase 3 | 412 | HutchmedINDUSTRY | 1 | Sep 22, 2026 | clinicaltrials |
| NCT05215548 | Primary Tumor Resection With EGFR TKI for Stage IV NSCLC | recruiting | Phase 2 | 100 | National Taiwan University HospitalOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT05696782 | Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer | recruiting | Phase 2 | 28 | Wake Forest University Health SciencesOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT05745740 | A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation | not yet recruiting | Phase 1 / Phase 2 | 26 | RemeGen Co., Ltd.INDUSTRY | 1 | Sep 22, 2026 | clinicaltrials |
| NCT06066138 | A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing | recruiting | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT06128551 | Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors | recruiting | Phase 1 / Phase 2 | 534 | Revolution Medicines, Inc.INDUSTRY | 7 | Sep 22, 2026 | clinicaltrials |
| NCT06140836 | A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3) | active not recruiting | Phase 3 | 190 | Bristol-Myers SquibbINDUSTRY | 21 | Sep 22, 2026 | clinicaltrials |
| NCT06151574 | Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment | active not recruiting | Phase 3 | 428 | Boehringer IngelheimINDUSTRY | 26 | Sep 22, 2026 | clinicaltrials |
| NCT06712316 | Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer | recruiting | Phase 2 / Phase 3 | 1,580 | BioNTech SEINDUSTRY | 22 | Sep 22, 2026 | clinicaltrials |
| NCT06714617 | Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors | terminated | Phase 1 | 3 | SystImmune Inc.INDUSTRY | 1 | Sep 22, 2026 | clinicaltrials |
| NCT06814496 | Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors(RABBIT) | recruiting | Phase 1 / Phase 2 | 30 | University of ArizonaOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT06875310 | A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4) | recruiting | Phase 3 | 630 | Mirati Therapeutics Inc.INDUSTRY | 35 | Sep 22, 2026 | clinicaltrials |
| NCT07028489 | Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer | recruiting | — | 130 | N-Power MedicineINDUSTRY | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07100080 | Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01) | recruiting | Phase 2 / Phase 3 | 500 | Bristol-Myers SquibbINDUSTRY | 25 | Sep 22, 2026 | clinicaltrials |
| NCT07104630 | Pulmonary Rehabilitation in Advanced Lung Cancer Survivors | recruiting | Phase 2 | 85 | Case Comprehensive Cancer CenterOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07174388 | An External Control Arm Study in Non-Small Cell Lung Cancer | recruiting | — | 650 | N-Power MedicineINDUSTRY | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07186699 | Qualitative Study on Detection & Tx of NSCLC in Pts w/ a History of Alcohol or SUD | recruiting | — | 45 | University of Southern CaliforniaOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07801508 | A Study of [68Ga]Ga-DWJ155 in Adult Patients With Solid Tumors | recruiting | Phase 1 | 66 | Novartis PharmaceuticalsINDUSTRY | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07816380 | A Phase III Study to Evaluate the Efficacy and Safety of JYP0322 in Previously Untreated ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer | not yet recruiting | Phase 3 | 216 | Guangzhou JOYO Pharma Co., LtdINDUSTRY | 0 | Sep 22, 2026 | clinicaltrials |
| NCT01350817 | Erlotinib and Docetaxel in Second Line of Treatment in Patients With Non Small Cell Lung Cancer(TARSEQ) | completed | Phase 2 | 156 | University Hospital, LimogesOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT04032418 | Pembrolizumab Every 12 Weeks Versus Every 3 Weeks in Treating Patients With Non-small Cell Lung Cancer | active not recruiting | Phase 2 | 9 | Roswell Park Cancer InstituteOTHER | 1 | Sep 21, 2026 | clinicaltrials |
Data updated 5 days agoSource updated Sep 24, 2026source: clinicaltrials